DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Semprex-D (Acrivastine / Pseudoephedrine Hydrochloride) - Indications and Dosage



SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials.

SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold.


The recommended dosage for adults and adolescents 12 years and older is one capsule administered orally, every 4 to 6 hours four times a day.


SEMPREX-D Capsules (dark green opaque cap and white opaque body with a yellow band) contain acrivastine 8 mg and pseudoephedrine hydrochloride 60 mg. The cap is printed with “404” in white ink, and the body is printed with “SEMPREX-D” in black ink.

NDC 53014-404-10 Bottle of 100’s


Store at 15° to 25° C (59° to 77° F) in a dry place and protected from light.

Keep out of the reach of children.

For Medical Information

Contact: Medical Affairs Department
Phone: (866) 822-0068
Fax: (770) 970-8859

Marketed by:

UCB, Inc.
Smyrna, GA 30080

Manufactured by:
DSM Pharmaceuticals, Inc.
Greenville, NC 27834 USA

SEMPREX is a registered trademark of UCB, Inc., Smyrna, GA 30080
© 2007, UCB, Inc., Smyrna, GA 30080
All rights reserved.

Rev. 1E 07/2007

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017